Galderma

Galderma, established in 1981, is a leading global dermatology company headquartered in Switzerland. It specializes in developing innovative medical solutions for a variety of skin conditions, including acne, rosacea, psoriasis, and skin cancer. The company was originally formed as a joint venture between Nestlé and L'Oréal but has been independent since 2019. Today, it operates under the ownership of a consortium of private institutional investors, including EQT and the Abu Dhabi Investment Authority. Galderma's extensive product portfolio includes well-known brands such as Cetaphil, Differin, Epiduo, Restylane, Sculptra, Dysport, and Soolantra. These products address both therapeutic and aesthetic dermatology needs, ranging from prescription medications to over-the-counter skincare solutions and injectable aesthetics. The company is committed to advancing dermatology through continuous research and development, boasting a robust pipeline of new treatments sourced from its global R&D centers located in Switzerland, Sweden, the United States, and Canada. With a presence in over 90 countries, Galderma employs around 6,600 people worldwide and continues to grow its influence in the dermatological field through partnerships and innovations. The company is dedicated to improving the quality of life for its consumers by offering safe, effective, and science-based skincare solutions.